Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
jRCT2080221890Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ly2886721 in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease (2 arms), sponsored by Eli Lilly and Company. Started Aug 2012; status: recruiting.
02
Drugs
ly2886721
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on jRCT2080221890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221890.